Becton Dickinson and Co (BDX) Shares Bought by James Hambro & Partners

James Hambro & Partners boosted its holdings in Becton Dickinson and Co (NYSE:BDX) by 129.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 71,509 shares of the medical instruments supplier’s stock after purchasing an additional 40,296 shares during the period. Becton Dickinson and comprises 6.5% of James Hambro & Partners’ holdings, making the stock its 8th largest position. James Hambro & Partners’ holdings in Becton Dickinson and were worth $18,657,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. FMR LLC lifted its position in shares of Becton Dickinson and by 13.7% during the 2nd quarter. FMR LLC now owns 16,987,638 shares of the medical instruments supplier’s stock valued at $4,069,559,000 after buying an additional 2,049,874 shares during the last quarter. Fundsmith Equity Fund L.P. purchased a new position in shares of Becton Dickinson and during the 2nd quarter valued at $894,775,000. Putnam Investments LLC lifted its position in shares of Becton Dickinson and by 0.5% during the 2nd quarter. Putnam Investments LLC now owns 3,513,485 shares of the medical instruments supplier’s stock valued at $841,690,000 after buying an additional 18,859 shares during the last quarter. Fiera Capital Corp lifted its position in shares of Becton Dickinson and by 1.7% during the 2nd quarter. Fiera Capital Corp now owns 2,801,767 shares of the medical instruments supplier’s stock valued at $671,192,000 after buying an additional 46,111 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Becton Dickinson and by 0.6% during the 2nd quarter. Bank of America Corp DE now owns 2,766,688 shares of the medical instruments supplier’s stock valued at $662,788,000 after buying an additional 15,603 shares during the last quarter. 92.51% of the stock is currently owned by institutional investors and hedge funds.

BDX has been the topic of a number of recent research reports. ValuEngine raised Becton Dickinson and from a “hold” rating to a “buy” rating in a research report on Tuesday, June 26th. Morgan Stanley upped their price target on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research report on Thursday, October 4th. KeyCorp reaffirmed a “buy” rating and set a $264.00 price target on shares of Becton Dickinson and in a research report on Friday, August 3rd. JPMorgan Chase & Co. raised Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price target on the stock in a research report on Thursday, June 21st. Finally, Citigroup upped their price target on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $255.40.

BDX traded down $3.88 during trading on Thursday, reaching $241.10. 7,014 shares of the company were exchanged, compared to its average volume of 1,160,385. The stock has a market capitalization of $69.83 billion, a price-to-earnings ratio of 25.47, a price-to-earnings-growth ratio of 1.78 and a beta of 1.11. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23. Becton Dickinson and Co has a 12-month low of $202.73 and a 12-month high of $265.87.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.86 by $0.05. The business had revenue of $4.28 billion for the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The firm’s quarterly revenue was up 41.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.46 EPS. On average, research analysts forecast that Becton Dickinson and Co will post 11.01 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 28th. Shareholders of record on Friday, September 7th were paid a $0.75 dividend. The ex-dividend date was Thursday, September 6th. This represents a $3.00 dividend on an annualized basis and a yield of 1.24%. Becton Dickinson and’s dividend payout ratio is currently 31.65%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Recommended Story: What is a Tariff?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply